Emergent BioSolutions Inc.
NYSE:EBSBiotechnology
-$0.21 today
- Market cap
- $282.78M
- Beta
- 2.33
- P/E (TTM)
- -47.9
- EPS (TTM)
- -$0.17
Volume 0.82M
Average 0.78M
EBS Retained Earnings
Cumulative profits kept in the business rather than paid out as dividends.
Emergent BioSolutions Inc.NYSE: EBS
Retained Earnings · Q1 FY2026 · quarter ended Mar 2026
Retained earnings remains negative
Q1 FY2026 retained earnings was -$153M, compared with -$144.4M a year earlier.
Context
- Retained earnings amounted to 11.6% of total assets at the end of Q1 FY2026, up 1.5 pp from a year earlier.
- Retained earnings increased in 1 of the last 3 fiscal years.
What to watch
Whether retained earnings keeps falling in the next quarterly balance sheet after a -6.0% change from a year earlier.
Sources:Balance SheetText generated from reported figures; not investment advice.
Retained Earnings history
USD · from the balance sheet
- Latest · FY2025
- (159.8M) USD
- Year-over-year change
- +24.8%
| Period | Period end | Retained Earnings | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | (159.8M) | +24.8% |
| FY2024 | 2024-12-31 | (212.4M) | -874.3% |
| FY2023 | 2023-12-31 | (21.8M) | -103.0% |
| FY2022 | 2022-12-31 | 738.7M | -22.3% |
| FY2021 | 2021-12-31 | 950.3M | — |
Retained Earnings vs competitors
How EBS compares with its peers on the latest reported figures
- Peers report in different currencies, so retained earnings is compared through growth and share of total assets rather than absolute size.
- Its year-over-year change of -6.0% is the 5th highest of 11, against a peer median of -12.3%.
- Retained earnings amounts to 11.6% of total assets for EBS, versus a peer median of 152.9%.
| Company | Period | Latest balance | YoY | 3-year CAGR | % of assets |
|---|---|---|---|---|---|
| Mar 2026 | -$56.23M USD | +4.6% | — | 10.8% | |
| Mar 2026 | -$90.44M USD | -289.1% | — | 41.2% | |
| Mar 2026 | -$153M USD | -6.0% | — | 11.6% | |
| Mar 2026 | -$425.99M USD | -11.6% | — | 168.2% | |
| Mar 2026 | -$455.06M USD | -17.8% | — | 322.4% | |
| Mar 2026 | -$650.65M USD | -39.8% | — | 122.6% | |
| Mar 2026 | -$731.39M USD | -32.4% | — | 137.5% | |
| Mar 2026 | -$1.01B USD | +26.4% | — | 201.0% | |
| Mar 2026 | -CA$1.28B CAD | +1.6% | — | 97.6% | |
| Mar 2026 | -$1.31B USD | -13.0% | — | 375.5% | |
| Mar 2026 | -$1.65B USD | -0.5% | — | 356.5% | |
| Peer median (excluding EBS) | — | -12.3% | — | 152.9% | |
Competitors are the stored peer set for EBS. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Balance Sheet
Metric | FY2021 Dec 2021 | FY2022 Dec 2022 | FY2023 Dec 2023 | FY2024 Dec 2024 | FY2025 Dec 2025 |
|---|---|---|---|---|---|
| Cash & Equivalents | 576.3M | 642.6M | 111.7M | 99.5M | 205.4M |
| Short-term Investments | 0 | 0 | 0 | 0 | 0 |
| Net Receivables | 278.9M | 159.2M | 191M | 154.5M | 84.2M |
| Inventory | 344.5M | 350.7M | 328.9M | 311.7M | 343.4M |
| Other Current Assets | 70.2M | 57.9M | 47.9M | 33M | 29.5M |
| Total Current Assets | 1.27B | 1.21B | 679.5M | 598.7M | 662.5M |
| Property, Plant & Equipment (Net) | 828.4M | 837M | 399M | 270.6M | 205.4M |
| Goodwill | 224.9M | 218.2M | 0 | 0 | 0 |
| Intangible Assets | 604.6M | 728.8M | 566.6M | 501.5M | 436.5M |
| Long-term Investments | 0 | 0 | 0 | 0 | 0 |
| Tax Assets | 0 | 0 | 0 | 0 | 0 |
| Other Non-current Assets | 29.9M | 171.9M | 178.1M | 18.9M | 14.2M |
| Total Non-current Assets | 1.69B | 1.96B | 1.14B | 791M | 656.1M |
| Total Assets | 2.96B | 3.17B | 1.82B | 1.39B | 1.32B |
| Account Payables | 128.9M | 103.5M | 112.2M | 60.9M | 55.6M |
| Short-term Debt | 37.4M | 963.1M | 413.7M | 2.7M | 0 |
| Tax Payables | 0 | 0 | 0 | 0 | 0 |
| Deferred Revenue | 11.7M | 26.4M | 0 | 0 | 0 |
| Other Current Liabilities | 107.3M | 48.6M | 106.8M | 81.1M | 76.6M |
| Total Current Liabilities | 374M | 1.23B | 651.3M | 162.4M | 132.2M |
| Long-term Debt | 809.4M | 448.5M | 446.5M | 663.7M | 572.1M |
| Deferred Tax Liabilities | 93.3M | 59.7M | 47.2M | 41.7M | 37.8M |
| Deferred Revenue (Non-current) | 4.7M | 0 | 0 | 0 | 0 |
| Other Non-current Liabilities | 40.6M | 26.7M | 28.9M | 29.4M | 53.9M |
| Total Non-current Liabilities | 972.2M | 549.7M | 522.6M | 744.5M | 663.8M |
| Total Liabilities | 1.35B | 1.78B | 1.17B | 906.9M | 796M |
| Common Stock | 100K | 100K | 100K | 100K | 100K |
| Retained Earnings | 950.3M | 738.7M | (21.8M) | (212.4M) | (159.8M) |
| Accumulated OCI | (16.1M) | 3.1M | (5.7M) | (5.2M) | (7.5M) |
| Other Stockholders Equity | 0 | 0 | 0 | 0 | 0 |
| Minority Interest | 0 | 0 | 0 | 0 | 0 |
| Total Equity | 1.61B | 1.39B | 649.3M | 482.8M | 522.6M |
| Total Debt | 871M | 1.43B | 860.2M | 676.1M | 572.1M |
| Net Debt | 294.7M | 783.8M | 748.5M | 576.6M | 366.7M |
Emergent BioSolutions Inc.
NYSE:EBS
Intrinsic Alpha fair value
Locked
Current Price
$5.50
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.